The present invention addresses the problem of providing a novel therapeutic strategy which has excellent therapeutic effects on systemic bone diseases caused by over-activation of FGFR3, in particular, achondroplasia and hypochondroplasia. A therapeutic agent for systemic bone disease is provided which comprises, as an active ingredient, meclizine or a pharmaceutically acceptable salt thereof.El objetivo es proporcionar una estrategia terapéutica novedosa que logre un efecto terapéutico alto sobre una displasia esquelética causada por la activación excesiva de FGFR3, particularmente la acondroplasia y la hipocondroplasia. Se proporciona un agente terapéutico para una displasia esquelética que incluye meclizina o su sal farmacéuticamente aceptable como un ingrediente activo.
